ALFA Finder| Revenue growth | 6.9% YoY for FY26; non-GPL business grew 13%. |
|---|---|
| Margins | Record 33.6% FY26 EBITDA margin, up 360bps YoY. |
| Order book | Closing 2 new CDMO deals expected in H2 FY27. |
| Demand visibility | Pretty good across regulated markets and CDMO segment. |
| Management confidence | High; confident in sustaining 30-32% margins despite headwinds. |
Growth
FY26 revenue grew 6.9% to ₹2,552cr; PAT stood at ₹565cr with 22.1% margins; EBITDA up 19.6% YoY.
Outlook
Guided 30-32% EBITDA margins; ₹540cr FY27 capex plan; Solapur Phase 1 operational by Q2 FY27.
Risks
Geopolitical conflicts impacting supply chains, elevated logistics/energy costs, and raw material price inflation (solvents).
Earnings Call filed with BSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,454.90
- Market cap
- ₹17,891 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 26.7×Sector 43.8×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Acquisition
Alivus Life Sciences signed a Shareholders' Agreement with IQGEN-X Pharma and its continuing shareholders. It governs inter se rights after the company's 76% IQGEN-X stake purchase.
Alivus Life Sciences Promoter Selling
Nirma Limited, a promoter of Alivus Life Sciences, sold 36,80,000 shares (2.99%) in the open market on 6 November 2026. Promoter holding falls from 74.73% to 71.74%.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong revenue growth driven by new products and CDMO traction, though margins were inflated by one-time income.
- Call
- Guides 11% growth
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.